Alexion Pharmaceuticals Inc. (ALXN) Downgraded by Vetr Inc. to “Strong Sell”
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was downgraded by stock analysts at Vetr from a “sell” rating to a “strong sell” rating in a research note issued on Tuesday. They currently have a $107.00 price objective on the biopharmaceutical company’s stock. Vetr‘s price target points to a potential downside of 11.86% from the company’s previous close.
ALXN has been the topic of a number of other research reports. Credit Suisse Group AG upgraded Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research report on Saturday, July 9th. Royal Bank Of Canada started coverage on Alexion Pharmaceuticals in a research report on Tuesday, July 12th. They set an “outperform” rating and a $188.00 price objective on the stock. Leerink Swann boosted their price objective on Alexion Pharmaceuticals from $210.00 to $211.00 and gave the stock an “outperform” rating in a research report on Monday, September 26th. Cowen and Company restated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Thursday, September 22nd. Finally, Jefferies Group restated a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, August 9th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $176.10.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 1.57% during trading on Tuesday, reaching $121.34. 1,130,164 shares of the company’s stock were exchanged. The stock’s 50-day moving average price is $125.47 and its 200-day moving average price is $134.10. The company has a market capitalization of $27.21 billion, a price-to-earnings ratio of 304.87 and a beta of 1.33. Alexion Pharmaceuticals has a 52-week low of $110.56 and a 52-week high of $193.45.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/19/alexion-pharmaceuticals-inc-alxn-downgraded-by-vetr-inc-to-strong-sell.html
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.17 by $0.04. The firm had revenue of $753 million for the quarter, compared to analyst estimates of $743.18 million. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. The business’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.44 earnings per share. Equities analysts expect that Alexion Pharmaceuticals will post $4.67 earnings per share for the current year.
In related news, SVP Heidi L. Wagner sold 222 shares of the stock in a transaction on Monday, August 8th. The stock was sold at an average price of $137.14, for a total value of $30,445.08. Following the sale, the senior vice president now owns 32,115 shares in the company, valued at $4,404,251.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Carsten Thiel sold 4,584 shares of the stock in a transaction on Friday, October 14th. The stock was sold at an average price of $120.28, for a total value of $551,363.52. Following the completion of the sale, the executive vice president now owns 32,741 shares in the company, valued at approximately $3,938,087.48. The disclosure for this sale can be found here. 4.41% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can purchased a new position in Alexion Pharmaceuticals during the second quarter worth approximately $34,314,000. Legal & General Group Plc boosted its position in shares of Alexion Pharmaceuticals by 4.0% in the first quarter. Legal & General Group Plc now owns 920,520 shares of the biopharmaceutical company’s stock worth $128,153,000 after buying an additional 35,267 shares during the period. Strs Ohio boosted its position in shares of Alexion Pharmaceuticals by 10.4% in the second quarter. Strs Ohio now owns 560,109 shares of the biopharmaceutical company’s stock worth $65,398,000 after buying an additional 52,710 shares during the period. Gateway Investment Advisers LLC boosted its position in shares of Alexion Pharmaceuticals by 14.2% in the second quarter. Gateway Investment Advisers LLC now owns 184,840 shares of the biopharmaceutical company’s stock worth $21,582,000 after buying an additional 23,032 shares during the period. Finally, Candriam Luxembourg S.C.A. boosted its position in shares of Alexion Pharmaceuticals by 4.4% in the second quarter. Candriam Luxembourg S.C.A. now owns 143,411 shares of the biopharmaceutical company’s stock worth $16,745,000 after buying an additional 6,017 shares during the period. 96.36% of the stock is currently owned by institutional investors and hedge funds.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.